$PBIO Patented Tech Enhances Nanoemulsion Bioavailability

March 12, 2018

• Patented UST process produces highly stable, clean and cost-effective nanoemulsions
• Technology can be applied across many industries, including pharmaceutical, food, nutraceutical, industrial lubricant, paint and cosmetic sectors
• UST technology aligns with consumer demand for chemical- and preservative-free products

The demand for nanoemulsions is growing at a fast pace, with potential applications in many industry sectors, including food, pharmaceuticals, nutraceuticals, cosmetics and industrial lubricants. Up to now, one of the major problems with nanoemulsions has been their instability. This instability compromises the bioavailability and absorption of active ingredients for product preparation and the shelf life of the product. Life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) is positioned to change this landscape via a patented novel technique called Ultra Shear Technology (“UST”). This technology uses intense shear forces generated by high-pressure valve discharge, which can help produce nanoemulsions that exhibit significantly improved absorption, greater stability and increased bioavailability compared to traditional micro and macro-emulsions.

Emulsions are mixtures of two liquids which are largely immiscible without the aid of emulsifying chemicals, such as surfactants. Surfactants assist in the dispersion of one liquid within the other, where it exists as tiny droplets. The smaller the droplet size for any given volume of dispersed liquid, the greater the absorption and bioavailability of active compounds. Nanoemulsions produce dispersed droplets with exceptionally small diameters, measured in nanometers.

To date, cost-effective, highly stable nanoemulsions made with minimal or no surfactants have been difficult to produce. Pressure BioSciences’ UST enables manufacturers to produce nanoemulsions at industrial scale levels that virtually exclude the use of surfactants, leading to safer and more effective oral delivery of food and medical products. This is a big deal in today’s world, where consumers across the globe are focusing more on wellbeing and demanding food that is appealing, tastes good, is free of chemicals and is safe to eat. Nanoemulsions produced using UST facilitate the production of food products with enhanced shelf lives and without the need for chemicals or preservatives. This groundbreaking technology will also increase product quality and shelf life in the pharmaceutical, nutraceutical and cosmetic sectors.

In October 2017, Pressure BioSciences concluded a strategic collaboration agreement with Phasex Corporation that will allow for the production of stable, water-soluble nanoemulsions that are expected to significantly improve drug and active ingredient delivery in the pharmaceutical, nutraceutical and cannabis oil industries. Aqueous nanoemulsions have the potential to increase the absorption and bioavailability of water-insoluble compounds like vitamin A, vitamin C and cannabinoids such as CBD. Phasex’s expertise lies in supercritical fluid (“SCF”) extraction processes that can be used for the manufacture of an extensive range of fine chemicals, polymers and natural extracts for pharmaceutical and nutraceutical formulations. SCF technology enables solvent-free extraction of active ingredients, which substantially enhances the quality of nanoemulsions.

Although the UST platform offers very exciting opportunities for future growth, Pressure BioSciences is not dependent on its novel UST platform for its future success. To that point, the company has been showing solid growth over the past several years in its’ primary product line, which is based on its innovative, patented, enabling platform called Pressure Cycling Technology (“PCT”). This technology uses cycles of hydrostatic pressure from ambient to ultra-high pressure levels to control bio-molecular interactions. It can be applied in several emerging life science areas, including:

• Sample preparation for genomic, proteomic and small molecule studies
• Control of biochemical reactions
• Protein purification
• Pathogen inactivation
• Immunodiagnostics

Patents for this technology have been issued to PBIO from many countries around the world, including China, Japan, multiple European countries, Canada, and the U.S. To date, the company has installed almost 300 PCT systems in more than 150 pharmaceutical, academic, biotechnological and government laboratories worldwide. Primary applications for the technology are in biomarker discovery, forensics, pathology and agriculture. The company has reported annual revenue of greater than $2 million, even though it has had but one sales person and one PCT instrument to sell. Recently, however, the company added four additional sales reps and has announced plans to release up to four additional instruments in 2018. These changes have set the company up for what could be significant future growth and an excellent return on investment for shareholders.

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Linker Tech Mimics Body’s Production of Pain Relieving Peptides
• Global Payout Inc. (GOHE) has Many Fingers in the Fintech Pie
• ChineseInvestors.com, Inc. (CIIX) Turns Focus to Growth of Cryptocurrency and Blockchain Technology, Financial Consulting Division

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$PVOTF Agro-Biotech Dealer’s License Application Filing

Dr. Wolfgang Renz Appointed Pivot’s Chief Medical Officer

VANCOUVER, British Columbia, March 12, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (FRA:NPAT) (“Pivot” or the “Company”), is pleased to announce that the Company has retained Cannabis Compliance Inc. (“CCI”) to submit an application to Health Canada for a Dealer’s License (“Dealer’s License” or “DL”) under the Controlled Drugs and Substances Act (“CDSA”) and the Narcotic Control Regulations enacted thereunder on behalf of Agro-Biotech Inc. (“Agro-Biotech”). As previously announced on February 22, 2018, Pivot has entered into a letter of intent for the proposed acquisition of Agro-Biotech (the “Proposed Acquisition”). For further details on the Proposed Acquisition, please refer to the Company’s news release.

Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility located in Saint-Eustache, Québec, 40 kilometres north of Montréal. Phase I is now complete and Phase II and Phase III are expected to be completed by the end of September 2018, resulting in a total grow area of 75,000 square feet, capable of producing a cumulative 10,000 kg per year. Agro-Biotech received its Producer’s License from Health Canada’s Office of Medical Cannabis on January 12, 2018. Upon the anticipated issuance of a Sales License from Health Canada, initial revenue is expected in Q3 2018.

Upon completion of the Proposed Acquisition, the Dealer’s License will enable Pivot, through Agro-Biotech, to conduct research and development (“R&D”) and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). A Dealer’s License and export permit would position the Company to export cannabis oils and concentrates to available international markets, as well as to process natural health products. In addition, a DL will also allow the Company to prepare authorized manipulations, formulations, dosage forms, strengths or package sizes of cannabis expanding possible research and product innovation opportunities.

The facility design includes extraction and purification areas expected to be fully operational following the successful closing of the Proposed Acquisition and receipt by Agro-Biotech of a Dealer’s License from Health Canada. Agro-Biotech is one of only six Licensed Producers in Québec, Canada’s second largest province with a population of over 8.4 million people. Owners of 75 high quality cannabis strains, including high expressors of CBD, Agro-Biotech’s genetics will enable it to bring unique, differentiated cannabis products to market.

Pivot is also pleased to announce that Dr. Wolfgang Renz has been appointed as the Company’s Chief Medical Officer. Dr. Renz previously served as Corporate Vice President, Healthcare Innovation, at Boehringer Ingelheim. He also serves as Adjunct Professor of Surgery at McGill University’s Faculty of Medicine in Montreal. Dr. Renz holds a M.D. and Ph.D from Freiburg University and is board certified in Germany in Emergency Medicine.
“I am excited to lead the development of all medical and therapeutic activities from Pivot’s impressive bio-cannabis pipeline,” Dr. Renz said. “There is tremendous value and opportunity based on the numerous product formulation and dosing technologies Pivot has licensed or acquired over the past year. The technologies have demonstrated their usefulness in the pharmaceutical markets and delivering cannabinoids with these platforms will be disruptive.”

Dr. Patrick Frankham, Pivot’s CEO states, “The addition of a Dealer’s License for the Agro-Biotech facility will allow the Company to exercise complete control of our finished products, from seed to derivatives. With access to 10,000 kg of cannabis annually, the ability to extract, purify and formulate in-house, Pivot will provide the most exceptional quality, dosable products available on the market. This vertical integration makes Pivot a differentiated player in the cannabis industry.”

Dr. Frankham added that, “The appointment of Dr. Renz provides Pivot with an experienced pharmaceutical executive who will accelerate the Company’s technological, marketing, sales and distribution partnerships in the European Union. We continue to aggressively execute on our business strategy.”

About Cannabis Compliance Inc.

Cannabis Compliance Inc. offers risk mitigation, due diligence and regulatory compliance for commercial cannabis producers and resellers around the world. We focus in the global market, and provide our clients with trusted and comprehensive solutions. CCI has extensive expertise in regulatory compliance, cultivation/horticulture, security designs/tender, facility designs/build-outs, quality assurance programs, import & export, staff recruitment and financial planning. CCI exists to empower the future leaders in the global cannabis industry. For more information please visit www.cannabiscomplianceinc.com.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.pivotpharma.com.

Cautionary Statement

Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, Pivot Green Stream, Agro-Biotech, or their respective management, identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated revenue and costs synergies associated with the acquisition of Agro-Biotech, statements with respect to internal expectations, including with respect to the Dealer’s License, estimated margins, expectations for future growing capacity and costs, the completion of any capital project or expansions, the timing for the completion of the Proposed Transaction, the ability of the Company to complete a financing in order to satisfy its financial obligations under the Proposed Transaction and expectations with respect to future production costs. In particular, there can be no assurance that the Proposed Transaction will be completed. Forward looking statements are based on certain assumptions regarding Agro-Biotech, including expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; the possibility that the Company be unable to successfully integrate Agro-Biotech as described herein; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Any forward-looking statements or facts (including financial information) related to Agro-Biotech discussed or disclosed herein are derived from information obtained directly from Agro-Biotech and publicly available sources and has not been independently verified by the Company. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$NETE Brings Jon Najarian on Board, Mobile Payments Market, Financial Review

NEW YORK, NY / March 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Net Element, Inc. (NASDAQ: NETE), a technology-driven group providing mobile payments and transactional services. The Company’s products and services include mobile payments, value-added services, marketing solutions and business analytics.

The company enables merchants of all sizes to accept and process over 100 different payment options in more than 120 currencies, including credit, debit, and prepaid payments. They provide merchants with value-added services and technologies including integrated payment technologies, POS solutions, security solutions, fraud management, information solutions and analytical tools. Their business is characterized by transaction related fees and multi-year contracts.

The Company has been focused on the development of the blockchain technology solutions and has not made any commitment related to any digital securities offering and/or an initial coin offering.

Read about the mobile payments market, and the NETE product portfolio here READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2FGP5Iu-NETE-Analyst

On March 7, 2018, the Board of Directors of Net Element, Inc. appointed, effective March 8, 2018, Mr. Jon Najarian as a Director of the Company and as a member of the Company’s Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. Mr. Najarian, who is 60 years old, is an accomplished financial industry veteran with more than 31 years of financial and capital markets industry experience. He is also a host of the International ICO Channel, a part of CoinBoost, whose goal is to bridge the divide between blockchain and mainstream media by offering distribution to traditional financial media outlets. Mr. Najarian is a cast member of CNBC’s “Halftime Report” and the “Fast Money” show. He is also the feature of the “DRJ Report” on CBOE-TV popular webcast.

Get info about the Appointment of Jon Najarian and a financial review READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2FGP5Iu-NETE-Analyst

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Brindha Dhanabalan, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

$WLDN to Participate in 30th Annual ROTH Conference

ANAHEIM, Calif.

Willdan Group, Inc. (“Willdan”) (NASDAQ: WLDN), a provider of professional technical and consulting services, today announced that it will participate in the 30^th Annual ROTH Conference in Orange County on Monday, March 12, 2018. During the conference, Willdan will make a presentation and hold a series of meetings with institutional investors. The Willdan Group presentation is scheduled for 5:30 p.m. PT.

A live webcast of the presentation will be available on the company’s website at www.willdan.com under the “Investors: Events and Presentations” section. An archived version will be available in the same location shortly after the conclusion of the presentation.

About Willdan Group, Inc.

Willdan provides professional consulting and technical services to utilities, public agencies and private industry throughout the United States. The Company’s service offerings span a broad set of complementary disciplines that include energy efficiency and sustainability, engineering and planning, financial and economic consulting, and national preparedness. Willdan provides integrated technical solutions to extend the reach and resources of its clients, and provides all services through its subsidiaries specialized in each segment. For additional information, visit Willdan’s website at http://www.willdan.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005161/en/

$PIXY Leveraging FinTech Innovation Proving to be Critically Valuable

Palm Beach, FL – (March 9, 2018) — FinTech has asserted itself as an essential technology within the financial services, payment services, human capital and a growing number of sectors for various reasons. According to a report recently issued by PwC, over 77% of companies globally intend to expand their efforts to innovate their fintech approach within the next three to five years. Prominent areas of various industries that are poised to be disrupted by fintech applications include human capital services, workforce applications, banking & financial, insurance, digital transactions and payment services. The World Economic Forum has led the creation of an industry consortium focused on improving the cybersecurity of a increasing number of technology companies, as collaboration between fintechs and financial institutions as a heightened need for companies to implement sturdy cybersecurity measures. FinTech Innovation coupled with Blockchain technology has the potential to universally reshape the way business transacts across nearly every industry in the global economy for companies such as: ShiftPixy, Inc. (NASDAQ: PIXY), PayPal Holdings Inc. (NASDAQ: PYPL), Starbucks Corporation (NASDAQ: SBUX), Square Inc. (NYSE: SQ), American Express Company (NYSE: AXP).

ShiftPixy, Inc. (NASDAQ: PIXY) BREAKING NEWS: Shiftpixy, amidst all the talk about the fintech boom, is developing a unique financial and insurance transaction and metering platform.

ShiftPixy’s technology platform leverages a “micro-metering” approach to incremental financial and payment transactions and related insurance coverages based on real-time use and exposures. In his discussion regarding ShiftPixy’s underlying technology in the midst of the fintech frenzy, ShiftPixy’s CEO Scott Absher stated, “We are preparing to operate at the level at which many fintech companies are endeavoring to attain. In connecting a workforce with business, ShiftPixy will be leveraging two critical technology functionalities. The first is what we call ‘micro metering’ of essential commercial insurance coverages required by our operator clients—namely workers’ compensation and auto coverages on a delivery-by-delivery basis. The second is using ShiftPixy’s blockchain ledger to process and record our critical P2P connections.” Read this and more news for ShiftPixy at http://www.marketnewsupdates.com/news/pixy.html

Mr. Absher went on to say, “The ShiftPixy mobile ecosystem’s success requires technical precision in managing sometimes relatively small yet frequent transactions that are growing in volume. Our ‘micro metering’ technology has caught the attention of the insurance community with its real time data visibility and its ability to scale at a rapid rate. Our blockchain technology assures that with rapid growth and scale, our essential security is keeping pace with the growth.”

ShiftPixy’s technology is engineered to allow the Company’s business operator clients to liberate and accelerate their business and thrive despite the gig economy changes affecting their businesses. ShiftPixy is allowing traditional retail and restaurant operators to connect and compete with ease in the part-time labor markets without technology investments.

Additional industry related developments from around the markets:

Village Capital and PayPal Holdings Inc. (NASDAQ: PYPL) have chosen 12 startups to take part in their first fintech accelerator in Sub-Saharan Africa, which will provide three months of training and offer US$50,000 investment in the best two companies. A cohort of 12 early-stage fintech startups has now been chosen from 165 applicants, each of which has developed an innovative technology or business model that has improved financial health for consumers or businesses. The cohort includes four startups from Kenya, namely tech platform for small scale producers Annona, foreign exchange service FPESA, insurtech startup GrassRoots Bima, and agriculture marketplace Tulaa, which is also active in Ghana.

Starbucks Corporation (NASDAQ: SBUX) recently addressed the company’s future intentions to become more involved in the fintech landscape through blockchain. “I think Blockchain technology is probably the rails in which an integrated app at Starbucks will be sitting on top of,” he said. For Starbucks to be considering how to incorporate Blockchain into its payment processes isn’t that much of a surprise. That’ because the coffee behemoth has a reputation for being willing to step into unchartered waters when it comes to technology. For example, it was one of the first major retailers to employ technology that allows customers to make their purchases with their mobile phones. It rolled out what it called the “nation’s largest mobile payment program” in 2010. A year later, it boasted that its mobile transactions topped 26 million within the first year.

Square Inc. (NYSE: SQ) is reportedly supporting direct deposits for paychecks, which means it’s one step closer to becoming a fully functional bank account, without actually being a bank account. Users just need to give their employer their account and routing number (found in Cash settings), and the app will notify them when a deposit hits their account. The funds are added to their regular Cash balance and can be spent via debit card, sent to a friend, put into another account or even used to buy bitcoin. This is a big step forward for Cash app — and the financial services sector in general. As long as you don’t need to deposit a cheque or wire a transfer (and who in this day and age does?) it’s now entirely possible to rely on the app in lieu of a traditional bank account, which is helpful for younger users entering their first job, those in underserved areas, or anyone reluctant to pay fees at more mainstream institutions. It’s not so straightforward for Square itself, though, as it doesn’t yet have its own bank charter, so it’s had to figure out quite a few workarounds to adhere to legislation. But as more and more fintech companies pioneer these kinds of services and see large-scale take-up, it might not be too long before at least some of the rules are reformed. Source: engadget

American Express Company (NYSE: AXP) recently joined the financial funding round of Even Financial, a technology platform powering financial services online. “Even Financial helps financial services providers and fintech partners programmatically deliver products and services in real time to the right customers when and where it’s most effective,” said Harshul Sanghi, Managing Partner of American Express Ventures. “By providing the underlying technology for more efficient customer acquisition, Even’s platform is enabling financial institutions to broaden their reach while connecting fintech partners with a greater supply of financial institutions and their products. We’re pleased to support Even in its efforts to expand its capabilities and grow its client base.”

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty five hundred dollars for news coverage of the current press release issued above by ShiftPixy, Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:
Media Contact email: info@marketnewsupdates.com – +1(561)325-8757

$NETE Today’s Research Reports on Stocks to Watch: Tech Data Corporation and Net Element

NEW YORK, NY / March 9, 2018 / Shares of Tech Data Corporation were in the red on Thursday after reporting a miss in its earnings for the fourth quarter. Shares of Net Element were soaring high after it was announced that a CNBC host is joining the company’s board.

RDI Initiates Coverage on:

Tech Data Corporation
https://rdinvesting.com/report/?ticker=TECD

Net Element, Inc.
https://rdinvesting.com/report/?ticker=NETE

Tech Data Corporation shares closed down 19.72% on about 3 million shares traded yesterday. Trading volume was significant compared to the stock’s average trading volume of just around 269,000 shares. Shares dropped after the Florida-based information technology products distribution company announced its fourth quarter financial report. For the quarter, Tech Data saw a profit of $1.3 million. Adjusted earnings were $3.50 a share, which was slightly below the $3.53 that analysts had expected. Revenue for the quarter at $11.09 billion was however higher than the $10.54 billion that analysts had anticipated. For the full year, there was a profit of $116.6 million, or $3.05 per share. Adjusted EPS was reported at $9.11 per share. Revenue was $36.78 billion. Looking ahead, the company expects adjusted EPS in the range of $1.30 to $1.60 for the first quarter that ends in May. Revenue is expected to be in the range of $8 billion to $8.3 billion. Since the year began, shares are down over 11%.

Access RDI’s Tech Data Corporation Research Report at:
https://rdinvesting.com/report/?ticker=TECD

Net Element, Inc. shares closed up 71.69% on about 8.6 million shares traded on Thursday. It was a big gaining day for the company’s shares after it was revealed that CNBC host Jon Najarian has joined its board of directors. Najarian is featured as a regular on CNBC’s “Halftime Report” as well as “Fast Money.” CEO Oleg Firer stated, “We are excited to have Jon join our board. He brings extensive financial, capital markets, cryptocurrency and blockchain insights to Net Element, and we look forward to his advice and direction as we move ahead with corporate initiatives.” Najarian commented, “I am impressed with Net Element’s technologies and its goals to disrupt the payments industry through innovation and value-added service offerings that include its recently announced plans for a decentralized blockchain platform. I am excited for what the future holds for Net Element, and am eager to support and advise on the Company’s current strategy. I look forward to joining the team.”

Access RDI’s Net Element, Inc. Research Report at:
https://rdinvesting.com/report/?ticker=NETE

Our Actionable Research on Tech Data Corporation (NASDAQ: TECD) and Net Element, Inc. (NASDAQ: NETE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

$ETST Enlarges Its Footprint in Hemp-Based CBD Market

March 9, 2018

• Agreement with Mr. Checkout will significantly strengthen the company’s product distribution network
• Human trials launched evaluating CBD-based therapy for opioid addiction
• Application made to uplist to OTCQB in early 2018, attracting more investment

The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://cnw.fm/kaL9i). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.

Following a revamp of its CBD product line, Earth Science Tech announced on February 13, 2018, that it had concluded an agreement with Mr. Checkout for the distribution of its products via major retailers and stores across the United States. This agreement will strengthen the company’s distribution network, which currently has 10 active representatives targeting distribution to health food stores and clinics. Mr. Checkout is a national group of independent distributors of products to over 60 major retailers and 55,000 stores. It will market ETST’s product line to major retailers such as Walmart, Walgreens and Target.

Earth Science Tech is a biotechnology company focused on the research and development of hemp-based CBD products for the pharmaceutical and nutraceutical industries. It also has a focus on the development of diagnostic tools and medical devices. On February 28, 2018, the company announced that it had finalized plans to conduct human trials on its new CBD-based formulation that targets opioid addiction (http://cnw.fm/rNnQ0). These trials will assess the efficacy of the combination of hemp-based CBD oil with an essential mineral element. Currently, the sole therapy for this condition is a monotherapy based on an essential mineral element. ETST’s formulation is expected to increase the potency and improve the outcome of this therapy.

The company operates through three wholly owned subsidiaries:

• Cannabis Therapeutics, Inc. which develops leading edge, cannabinoid-based products for the pharmaceutical and nutraceutical sectors;
• KannaBidioiD which is focused more on developing products for the recreational use of cannabis, including edibles, vapes and eLiquids;
• Earth Science Pharma, Inc., which develops medical devices and low-cost, noninvasive diagnostic tools, as well as testing processes and vaccines for sexually transmitted diseases.

Cannabis Therapeutics is in the development stage of two CBD-based pharmaceutical drugs and three CBD-based nutraceutical products. These will target a variety of ailments, including depression, anxiety, breast cancer and fatty liver disease. In October 2017, Earth Science Tech announced a collaboration with Clinique SIDA Amité to conduct a mini-trial on its MSN-2 device for the detection of Chlamydia. ETST has also acquired Canna Inno Laboratories Inc., based in Montreal, Canada, which will give the company the opportunity to expand into Canada and gain access to local government grants for pharmaceutical industry innovation.

Earth Science Tech expects to uplist to the OTCQB Venture Exchange in early 2018, which it believes will attract well-funded institutional investors. These recent developments are likely to increase company growth and enlarge Earth Science Tech’s presence in the cannabis industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• ChineseInvestors.com, Inc. (CIIX) Turns Focus to Growth of Cryptocurrency and Blockchain Technology, Financial Consulting Division
• Building a Portfolio of Industrial Hemp Companies is Key to the Future of Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF)
• Acquisitions and Growth Expand in Canadian Cannabis Market

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CIIX Turns Focus to Growth of Cryptocurrency and Blockchain Technology

March 9, 2018

• Company returning to its roots in financial consulting, corporate brand building and educational services for cryptocurrencies, such as bitcoin
• CIIX has daily video from NYSE targeted at its global Chinese-speaking investment community titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters
• Company is urging its shareholders to convert stock, on a four-for-one basis, for a share in the new, private company that includes hemp assets CBD Biotechnology Co. Ltd., Hemp Logic, Inc. and ChineseHempOil.com, Inc.

ChineseInvestors.com, Inc. (OTCQB: CIIX) will return to its roots as a financial consultant and a specialist in cryptocurrency, especially bitcoin, as it spins off its hemp assets into a private company. In a news release (http://nnw.fm/ux18M), Paul Dickman, CFO of CIIX, said, “This is a great time to spin off CIIX’s CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry.”

CIIX has in the past succeeded as a diverse company with multiple-focuses, but, with this spinoff, it can now concentrate on its core skills in brand building for startups and financial marketing for its clients.

The San Gabriel, California-based company specializes in financial education and marketing for the global Chinese-speaking investment community. It has an interest in the growth of cryptocurrency with a daily video newscast from the NYSE daily titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

Following the planned spinoff, CIIX intends to focus on those interests while giving its shareholders a special dividend. They may exchange four shares of CIIX common for one share in the new company, which consists of CIIX’s hemp-related assets. These include wholly owned foreign enterprise CBD Biotechnology Co., Ltd. and U.S.-based wholly owned subsidiaries Hemp Logic, Inc. and ChineseHempOil.com, Inc.

The four-for-one exchange of shares will be made effective on May 31, 2018, the date of the spinoff. The new company will initially be private, but CIIX has announced plans to bring the new company into the public market in the 12-18 months that follow (http://nnw.fm/Keo8c).

For more information, visit the company’s website at www.ChineseInvestors.com

More from NetworkNewsWire

• Blending the Virtual with the Practical by Building Green Energy with Solar Bankers and SunCoin ($SUN)
• Earth Science Tech, Inc. (ETST) Enlarges Its Footprint in Hemp-Based CBD Market
• Marifil Mines Ltd. (TSX.V: MFM) Maintains Optimism for Lithium, Cobalt and Gold in Famed South American Region

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$ACRX Receipt Of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA NDA

REDWOOD CITY, Calif., March 8, 2018 — AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the receipt of the official January 2018 Type A meeting minutes from the U.S. Food and Drug Administration (FDA) relating to AcelRx’s DSUVIA^™ New Drug Application (NDA).

At this meeting, AcelRx proposed potential resolutions for the two main points identified in the Complete Response Letter (CRL) received from the FDA in October 2017.  These main points were: (1) collect additional data in 50 patients with postoperative pain sufficient to evaluate the safety of DSUVIA at the maximum dosage in the proposed label, and (2) modify the Directions For Use (DFU) to mitigate the risk of misplaced tablets and validate the effectiveness of these changes in a human factors study.  To address the first point, AcelRx proposed instead to reduce the maximum dose in the label to not exceed 12 tablets within a 24-hour period to more closely match the clinical utilization of DSUVIA in the trials.  The Company proposed to the FDA that the existing data from the higher dosing patients in the DSUVIA and Zalviso clinical trials should be sufficient to evaluate the safety of DSUVIA at this reduced maximum available daily dose.  The FDA stated that the proposed revision to the maximum daily dosage appeared reasonable and that it was expected that the high-exposure DSUVIA patient data combined with the high-exposure Zalviso patient data may be sufficient to support safety at maximal dosing in the DSUVIA NDA resubmission.

To address the second point in the CRL, AcelRx submitted to the FDA an updated DFU, and a revised protocol for the human factors (HF) study required to validate the effectiveness of the DFU changes. The FDA has reviewed and recently provided its comments to the updated DFU and HF study protocol, and the Company expects this study to be completed next month.  In the NDA resubmission, AcelRx will provide these study results, along with the additional DSUVIA and Zalviso data analysis supporting the reduced maximum daily dosage. The Company intends to resubmit the NDA in the second quarter of 2018 after the completion of the HF study.

“We are pleased with the constructive nature of the meeting with the FDA, which has provided a clear path to resubmit the DSUVIA NDA, which we expect to accomplish in the second quarter of this year,” said Vince Angotti, CEO of AcelRx.  “Completing the HF study next month is now the priority to meet our resubmission timeline.  We continue to believe DSUVIA can satisfy a large unmet need within healthcare settings, and we remain focused on our mission to provide healthcare providers and patients with non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings,” continued Angotti.

Conference Call
As previously announced, AcelRx will conduct an investment-community conference call today, March 8, 2018 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its fourth quarter financial results at which time it will also discuss the outcome of the Type A FDA meeting. Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to a webcast of the conference call live via the Internet may do so by visiting the Investors page of the company’s website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be archived on the AcelRx website for 90 days following the call.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has two product candidates including DSUVIA^™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso^® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

For additional information about AcelRx’s clinical programs, please visit www.acelrx.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to the process and timing of an NDA resubmission for DSUVIA with the FDA, including the initiation and completion of the HF study as recommended in the FDA’s CRL. These forward-looking statements are based on AcelRx’s current expectations and involve significant risks and uncertainties. AcelRx’s actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including, without limitation: risks related to the ability to complete and achieve successful results from the proposed HF study in connection with the resubmission of the DSUVIA NDA to the FDA; the possibility that the FDA may dispute or interpret differently the results of the Company’s planned HF study to validate the effectiveness of the changes in the DFU, or the supplemental clinical information addressing the reduced maximum dosage to be included in the planned resubmission of the NDA for DSUVIA; any delays or inability to obtain and maintain regulatory approval of DSUVIA in the United States, DZUVEO in Europe and ZALVISO in the United States; and other risks detailed in the “Risk Factors” and elsewhere in AcelRx’s U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2017. AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

$DISCB Completes Acquisition Of Scripps Networks Interactive

Combination Creates a New Global Leader in Real Life Entertainment Across all Screens – Featuring five of the top female U.S. cable networks & reaching 20% of women watching primetime pay-TV – A platform innovator driving 7B average short- and mid-form monthly video views – Home of the Olympic Games and the Leader in Sports in Europe – Reaching passionate fans in 220 countries and territories and 50 languages with 8,000 hours of original programming

SILVER SPRING, Md., March 6, 2018 — Discovery Communications, Inc. (Nasdaq: DISCA, DISCB, DISCK) announced today that the company has successfully completed its acquisition of Scripps Networks Interactive, Inc. (Nasdaq: SNI). Moving forward, the combined company will be officially known as simply: Discovery, Inc.

“Today marks another critical milestone for Discovery, as we become a differentiated kind of media company with the most trusted portfolio of family-friendly brands around the globe,” said David Zaslav, President and Chief Executive Officer for Discovery. “As a new global leader in real life entertainment, Discovery will serve loyal and passionate audiences around the world with content that inspires, informs and entertains across every screen; deliver new ways for advertisers and distributors to reach highly targeted audiences at scale; and leverage our leadership position to create new value and growth opportunities for all of our stakeholders.”

The name change to Discovery, Inc. demonstrates a new focus on growth in the areas at which Discovery excels, telling stories across deeply loved genres and empowering superfans to explore their world wherever and whenever they choose.

The acquisition is expected to be accretive to adjusted earnings per share and to free cash flow in the first year after closing, including significant cost synergies. The combination is expected to create a strong economic model with capacity for rapid debt repayment and a clear runway for growth and value creation.

Kenneth W. Lowe, former Chairman, President & CEO of Scripps Networks Interactive, will join Discovery’s board of directors, effective immediately.

Scripps shareholders will receive approximately $90 per share, consisting of $65.82 per share in cash and 1.0584 per share in Series C Common shares of Discovery stock valued based on a volume weighted average price (subject to elections and proration), in each case in accordance with the terms of the merger agreement.  This includes a cash payment of $2.82 per share in connection with Discovery’s previously announced decision to exercise in full the cash top-up option under the merger agreement.

About Discovery:
Discovery, Inc. (Nasdaq: DISCA, DISCB, DISCK) is a global leader in real life entertainment, serving a passionate audience of superfans around the world with content that inspires, informs and entertains. Discovery delivers over 8,000 hours of original programming each year and has category leadership across deeply loved content genres around the world. Available in 220 countries and territories and 50 languages, Discovery is a platform innovator, reaching viewers on all screens, including TV Everywhere products such as the GO portfolio of apps and Discovery Kids Play; direct-to-consumer streaming services such as Eurosport Player and Motor Trend OnDemand; and digital-first and social content from Group Nine Media. Discovery’s portfolio of premium brands includes Discovery Channel, HGTV, Food Network, TLC, Investigation Discovery, Travel Channel, Turbo/Velocity, Animal Planet, and Science Channel, as well as OWN: Oprah Winfrey Network in the U.S., Discovery Kids in Latin America, and Eurosport, the leading provider of locally relevant, premium sports and Home of the Olympic Games across Europe. For more information, please visit www.corporate.discovery.com and follow @DiscoveryInc across social platforms.

$DXR Announces Rise in Kit Sales, New Device Sale

New York, NY, March 08, 2018 — Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2017.

In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related to cardiology use as well as an uptrend in overall kit sales for blood volume usage across all indications. In addition, the Company sold a new BVA-100 system to Self Regional Healthcare of Greenwood, South Carolina for use in their cardiology department following a successful pilot program.

Dr. Priya V. Kumar, a cardiologist at Self Regional was previously quoted as saying: “The BVA-100 has significantly improved our management of heart failure patients. It has proved to be a valuable tool in assessing volume status in difficult heart failure patients, especially those that are obese and those that are in renal failure. The BVA-100 has provided us with a great non-invasive way to assess a patient’s volume status accurately.”

Michael Feldschuh, CEO of Daxor stated: “Sales are rising — driven by the combination of successful outcome studies, focused sales efforts, and our client hospitals’ pressing need for improved readmission and mortality outcomes.”

Recent developments for the company in the past six months include inclusion in industry drug trials, outcome studies by researchers at academic institutions on blood volume usage in multiple indications, as well as interest from US Government agencies to improve ICU and heart failure outcomes. Soren Thompson, VP of Business Development stated: “We are working with a growing number of researchers and partners interested in improving outcomes through the use of precision blood volume analysis. The BVA-100 is widely viewed as the gold standard in this area and we are excited about the future potential for our clinical, research, and other partnerships.  We are gratified there is increasing recognition of the urgent need for accurate individualized volume assessment to improve patient care and reduce hospital costs.”

Blood volume measurement is a fundamental tool for accurate diagnosis and treatment in a variety of medical and surgical conditions, such as congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia, as well as additional conditions.

Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit. The BVA -100 is the only FDA-cleared instrument which quantifies blood volume with 98% accuracy with results available in under an hour.  Over a dozen widespread medical conditions benefit from accurate volume assessment to guide therapy including heart failure and ICU use, the company has focused on sales in these areas.

Copies of the N-CSR form will be mailed to the Company’s shareholders and are filed with the SEC as well as on the Company’s website at http://www.daxor.com/wp-content/uploads/2018/03/Daxor-12-31-2017-FORM-N-CSR.pdf.

Contact Information:

Daxor Corporation:  Soren Thompson 212-330-8502 (Investor Relations) sthompson@daxor.com

$NETE Enables Global Commerce with Omni-Channel Payment Solution Platform

March 8, 2018

• Increasing acceptance of smartphones for mobile payments coincides with emerging markets’ transition to non-cash transactions
• Global mobile payments solutions market projected to reach $3.14 trillion by 2022, growing at a CAGR of 32 percent from 2017 to 2022
• Innovative payment infrastructure and services are globally oriented but adaptable to unique requirements of each country
• Omni-channel shoppers spend between 50 percent and 300 percent more than single shoppers

Net Element, Inc. (NASDAQ: NETE), a global technology company specializing in mobile payments and value-added transactional services, is growing rapidly as consumers and retailers around the globe embrace the security and ease of digital commerce. Net Element provides more than 100 electronic payment solutions for clients in 50 countries and plans to move into additional international markets. Several market research firms, including Statista (http://nnw.fm/kG8Wg), show that global transactions are soaring as consumers integrate mobile payment options into their daily routines.

Net Element and its team of engineers provide retailers with a disruptive, single commerce, all-in-one platform that supports multiple payment methods (http://nnw.fm/o0xEd). The company’s focus on developing innovative technology enables Net Element to grow its strategic position in a variety of emerging markets around the globe. Estimates of worldwide transaction volume vary depending on the research firm, but experts agree that mobile payment totals are expected to move into the billions of dollars (http://nnw.fm/hlq8X).

Retailers and customers alike can appreciate the omni-channel offerings of Net Element’s payment infrastructure, which allows the integration of in-store, online and mobile device apps that interact with the consumer’s evolving needs in mind (http://nnw.fm/mJo4n). A fully automated, encrypted payment solution that handles administration to configuration provides a secure and seamless cardholder transaction base for mobile purchases, while an exceptional collection of business analytics tools provides valuable information for today’s retailer that’s striving to make smarter decisions. Mobile payments are being used in a diverse range of business and consumer transactions, increasing exponentially as the proliferation of smart devices gains steam and consumers are offered the value-added benefits of mobile payments, according to Forrester Research Inc. (http://nnw.fm/I819v).

Net Element aims to grow transactional value by innovating productivity services for small to medium enterprises in the U.S. with its cloud-based restaurant and retail point-of-sale solution, Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. The company’s newest multi-channel payments platform – Netevia – provides end-to-end payment processing through user friendly APIs. In a news release, Andrey Krotov, Net Element’s chief technology officer, said that Netevia’s platform “delivers a blueprint and easy to use tools for global commerce and monetization, saving developers and merchants time and money with one provider and one integration across all sales channels.”

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• Building a Portfolio of Industrial Hemp Companies is Key to the Future of Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF)
• Graham Corp. (NYSE: GHM) Starts Presentation at LD Micro Virtual Event
• Rand Capital Corp. (NASDAQ: RAND) Starts Presentation at LD Micro Virtual Event

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$RGNX to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., March 07, 2018 — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will participate in the following March investor conferences:

Barclays Global Healthcare Conference
Date: Wednesday, March 14, 2018
Location: Loews Miami Beach Hotel, Miami, FL
Fireside chat: Wednesday, March 14, 2018 at 3:20 p.m. ET

Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 20, 2018
Location: Boston Harbor Hotel at Rowes Wharf, Boston, MA

A live webcast of the Barclays fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

$PIXY Blockchain Use Case

ShiftPixy, Inc. (NASDAQ: PIXY), a disruptive workforce engagement platform provider, is leveraging blockchain as a digital ledger for all human capital transactions. Blockchain is being met with skepticism due to the lack of use cases.

ShiftPixy is a prime use case for implementing a private, centralized blockchain due to the security and privacy of the data that a blockchain affords. In business, human capital transactions contain some of the most crucial and sensitive personal information-namely, everything contained in the personnel records for an individual (including social security number, date of birth, driver’s license or passport details, bank account information, tax form elections, and more). Any data considered to be a human capital validation point or part of the hiring and onboarding process is being utilized and recorded in ShiftPixy’s blockchain ledger. The employee I-9 verification process, for example-one of the most stringent, rigorous, and penalty-laden compliance procedures-is positively impacted by blockchain utilization of biometric authentication and automatic verification of I-9 data, removing human error in the process of screening for fraudulent information. Scott Absher, President and CEO of ShiftPixy, stated, “We use blockchain technology in our ecosystem, because it is one of the most efficient tools available to help us protect our data from cyber interference. Any data considered to be a human capital validation point or part of the hiring and onboarding process is being utilized and recorded in ShiftPixy’s blockchain ledger.”

The security and ability for auditing transparency afforded by the integrated blockchain technology is paramount to protecting both the employee and the ShiftPixy job providers in the ShiftPixy ecosystem. Verification of that data on the blockchain allows both employers and auditing agencies to confidently validate additional criteria such as employment dates, and a candidate’s background (i.e. education, references, certifications, etc.), and share the verification status directly on multiple distributed sources within the blockchain, further underscoring the trust and accuracy of a candidate’s information and corporate compliance. Added benefits for data integrity include allowing employees and shift workers to rate experiences at a workplace-also recorded in the blockchain’s transparent ledger, which gives the peace of mind that the review or rating cannot be tampered with (i.e. neither shifters nor companies can pay to change or remove unfavorable ratings). Future implementation of blockchain technology within ShiftPixy’s technological ecosystem include the extended applications for payroll and real-time payments, and utilizing smart contracts for employment contracts, which facilitate the performance of credible, trackable, and irreversible transactions without third parties.

Learn More

To discover the power of ShiftPixy for your business please select one of our convenient webinar timeslots at:

https://www.shiftpixy.com/webinars/ or call us at 888-798-9200 to register.

Note of Clarification

To be clear, ShiftPixy has never, does not now and will never use its blockchain technology in any form of cryptocurrency or cryptocurrency related application.

About ShiftPixy

ShiftPixy (NASDAQ: PIXY) is a disruptive human capital management platform, revolutionizing employment in the Gig Economy by delivering a next-gen mobile engagement technology to help businesses with shift-based employees navigate regulatory mandates, minimize administrative burdens and better connect with a ready-for-hire workforce. With expertise rooted in management’s nearly 25 years of workers’ compensation and compliance programs experience, ShiftPixy adds a needed layer for addressing compliance and continued demands for equitable employment practices in the growing Gig Economy.

ShiftPixy Cautionary Statement

The information provided in this release includes forward-looking statements, the achievement or success of which involves risks, uncertainties, and assumptions. Although such forward-looking statements are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate. If any of the risks or uncertainties, including those set forth below, materialize or if any of the assumptions proves incorrect, the results of ShiftPixy, Inc., could differ materially from the results expressed or implied by the forward-looking statements we make.  The risks and uncertainties include, but are not limited to, risks associated with the nature of our business model; our ability to execute the Company’s vision and growth strategy; our ability to attract and retain clients; our ability to assess and manage risks; changes in the law that affect our business and our ability to respond to such changes and incorporate them into our business model, as necessary; our ability to insure against and otherwise effectively manage risks that affect our business; competition; reliance on third-party systems and software; our ability to protect and maintain our intellectual property; and general developments in the economy and financial markets.  The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.  The information in this press release shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.  Further information on these and other factors that could affect the financial results of ShiftPixy, Inc., is included in the filings on Forms 1-A and 10-K and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the “SEC Filings” subsection of the “Investor Information” section of our website at https://ir.shiftpixy.com/financial-information/sec-filings.

Consistent with the SEC’s April 2013 guidance on using social media outlets like Facebook and Twitter to make corporate disclosures and announce key information in compliance with Regulation FD, ShiftPixy is alerting investors and other members of the general public that ShiftPixy will provide updates on operations and progress required to be disclosed under Regulation FD through its social media on Facebook, Twitter, LinkedIn and YouTube. Investors, potential investors, shareholders and individuals interested in our Company are encouraged to keep informed by following us on Facebook, Twitter, LinkedIn and YouTube.

Media Contact:
Clark Wilson
clark.wilson@shiftpixy.com
+1(949)-245-7250

$VSQTF Mehdi Khimji Announces Exercise of Warrants to Acquire Additional Common Shares

LONDON, March 06, 2018 — Mr. Mehdi Khimji announces that he has exercised his warrants to purchase an aggregate of 3,333,334 common shares (the “Purchased Shares”) in the capital of Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST)(OTC:VSQTF)(FWB:6F6). The Purchased Shares were acquired for CDN$1.50 per Purchased Share, representing an aggregate exercise price of CDN$5,000,001 (the “Proceeds”).

The Purchased Shares represent approximately 5.3% of the outstanding Common Shares. When combined with the 6,666,667 Common Shares Mr. Khimji already owns, Mr. Khimji will hold an aggregate of 10,000,001 Common Shares, representing approximately 15.2% of the issued and outstanding Common Shares.

Mr. Khimji exercised the warrants to purchase the securities for investment purposes and may or may not purchase or sell securities of the Company, in the future on the open market or in private transactions, depending on market conditions and other factors. Depending on market conditions, general economic and industry conditions, the Company’s business and financial condition and/or other relevant factors, Mr. Khimji may develop other plans or intentions in the future.

A copy of the early warning report filed in connection with the transaction will be available on the Company’s profile on SEDAR at www.sedar.com or may be obtained by contacting Rick Whitworth at 972-444-9700.

Rick Whitworth
972-444-9700

$ETST Subsidiary Receives Grant from the Government of Québec

DORAL, FL, March 07, 2018 — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that its Canadian subsidiary, Canna Inno Laboratories Inc. (the “Subsidiary”) has received a supporting grant for innovation in the pharmaceutical industry from the Ministère de l’économie, des sciences et de l’innovation of the Government of Québec.

ETST formed Canna Inno Laboratories Inc. in August 2017, a strategic Montreal, Canada-based company.  The Subsidiary gave the Company a foothold in Québec and provided ETST with access to government grants, the first of which have just been approved.

This first grant is earmarked for the pre-launch processes on the Company’s three CBD-based nutraceutical provisional patent products, announced in 2017. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once the pre-launch has been completed, the results will be applied as a patent pending, the logical step following our provisional patent. During the application process, the products will be commercialised as nutraceutical.

The company also plans to apply for more funding under Canada’s Scientific Research and Experimental Development Tax Credit program among others.

Dr. Michel Aube, the Company’s CEO & CSO states, “The province of Quebec is a fertile terrain for biotech companies. The creativity of the people and the quality of the infrastructure are the fruits of a strong collaboration between governmental organizations and companies. We enjoy being a part of this great network to help assist our studies to create innovative alternative medicine.”

About Earth Science Tech, Inc. (ETST)

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dave Demarest
305.546.7640 Office
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office

$DJACF Applies for Cannabis Oil License, Launches Innovative Extraction Program with Vitalis

TORONTO, March 7, 2018  – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE:HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to provide an update of the Company’s recent corporate development initiatives.

DOJA Applies for Cannabis Oil License and Signs Innovative Extraction Partnership Agreement with Vitalis

Hiku’s wholly-owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), submitted its application to Health Canada for the production of medical cannabis oils at its second site facility (the “FUTURE LAB“) located in Kelowna, British Columbia.

Hiku is also pleased to announce it has signed a strategic partnership agreement with Vitalis Extraction Technology Inc. (“Vitalis“), whereby Vitalis will advise on the build-out of DOJA’s extraction lab, partner on certain research and development initiatives, and supply the FUTURE LAB with Vitalis’ Q-90 supercritical CO2 extraction system – which is capable of processing up to 80 kg of cannabis flower per day into ultra-pure, exceptionally-clean, high-quality cannabis oils without the use of any toxic solvents. Vitalis is known as the leading manufacturer of high flow rate industrial supercritical CO2 extraction systems that are redefining the capabilities of traditional extraction methodologies.

“This is an important step for Hiku, the future of cannabis will be convenience and consistency, and the proliferation of dose-controlled consumption methods will be driven by oil and concentrate innovation,” said Alan Gertner, CEO of Hiku. “Vitalis has vast experience deploying supercritical CO2 extraction systems and is at the forefront of extraction innovation. We look forward to working with them to build out our state-of-the-art extraction lab and develop a diverse cannabis oil and concentrate offering.”

Once the FUTURE LAB is completed, Health Canada will be invited to conduct an inspection to secure an amendment permitting the production of cannabis oils.

Hiku Brings Prairies Tokyo Smoke Retail Expansion In-House After Prized Manitoba RFP Win

TS Brandco Holdings Inc. (“Tokyo Smoke“), Hiku’s wholly-owned subsidiary, with participation by BOBHQ, was conditionally awarded one of only four master retail licenses (the “License“) in Manitoba’s highly competitive Request for Proposal (“RFP“) process for the right to operate retail cannabis stores on February 16, 2018 (read more here). The License gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis sales platform in Manitoba. Hiku is committed to expanding Tokyo Smoke’s retail locations in Alberta, Manitoba, and Saskatchewan through company owned and operated stores and plans on participating in future cannabis retail licensing processes across the country under the Tokyo Smoke and DOJA brands to significantly grow Hiku’s national retail footprint.

Keeping with the Company’s strategic vision for cannabis retail, Hiku has acquired all of the issued and outstanding shares of TS Prairie Retail Corp., an entity that previously held exclusive rights to establish “Tokyo Smoke” branded stores in Alberta, Manitoba, and Saskatchewan under a license agreement dated August 15, 2017, pursuant to a share purchase agreement dated March 6, 2018 in exchange for 4.2 million common shares in the capital of Hiku.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led byTokyo Smoke, craft cannabis production throughDOJA‘s ACMPR licensed grow, andVan der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku has entered into supply partnerships with Aphria Inc. (TSX: APH) (OTCQB: APHQF) and WeedMD Inc. (TSXV: WMD) to ensure Hiku’s brands will be able to scale in 2018 and beyond.

About Vitalis

Vitalis is a Kelowna-based engineering and manufacturing company, producing the highest-flowing industrial supercritical CO2 extraction system for the cannabis market. The company’s core focus on innovation and design has vaulted it to the forefront of the market. Renowned for their reliability, scalability, and continuous operation, Vitalis systems are designed and manufactured in accordance with ASME and CSA Standards for Boiler, Pressure Vessel and Pressure Piping Code. The vessels are stamped with a CRN and NB registration number confirming that the vessels meet code and have been inspected by an Authorized Inspector. With systems on three continents, Vitalis has the most deployments of industrial CO2 supercritical extractors into the cannabis industry. Vitalis was recently voted Top Extraction Equipment at the 2017 Lift Canadian Cannabis Awards. For more information, visit their website at www.vitaliset.com.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding the ongoing relationship between the Company and Vitalis, the performance of Vitalis products and technology, the Company and Tokyo Smoke’s intention to expand retail locations in the Prairies, and the Company’s participation in future cannabis retail licensing processes. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

$CLSD Announces Proposed Public Offering of Common Stock

ALPHARETTA, Ga., March 06, 2018 — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million of shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Clearside.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Clearside intends to use the net proceeds of the offering to prepare and submit an NDA for suprachoroidal CLS-TA for the treatment of patients with macular edema associated with non-infectious uveitis and to invest in commercialization and marketing of suprachoroidal CLS-TA, if approved.   In addition, Clearside intends to use the net proceeds to continue its Phase 3 SAPPHIRE clinical trial for its RVO program, complete its Phase 2 TYBEE clinical trial for its DME program and initiate its second Phase 3 TOPAZ clinical trial for its RVO program, as well as for continued research and development of its earlier-stage programs, working capital and general corporate purposes.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.  Stifel, Nicolaus & Company, Incorporated is acting as a passive book-running manager and Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.  Clearside intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on July 3, 2017 and declared effective by the SEC on July 13, 2017.  The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.  A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com, or by phone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806, or by fax at (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefits to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Clearside, including statements about the Clearside’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in Clearside’s Annual Report on Form 10-K filed with the SEC on March 16, 2017 and other filings with the SEC under the heading “Risk Factors.”  In addition, the forward-looking statements included in this press release represent Clearside’s views as of the date hereof. Clearside anticipates that subsequent events and developments will cause Clearside’s views to change. However, while Clearside may elect to update these forward-looking statements at some point in the future, Clearside specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Clearside’s views as of any date subsequent to the date hereof.

Contacts:
Stephen Kilmer
Investor Relations
(678) 270-3631
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
(678) 270-4005
charlie.deignan@clearsidebio.com

$AMTX Completes Operation of Cellulosic Ethanol Integrated Demonstration Unit

CUPERTINO, CA / March 6, 2018 / Aemetis, Inc. (NASDAQ: AMTX) announced today that the company successfully built and operated an integrated demonstration unit for more than 120 days of continuous operations with 94% uptime, meeting the requirements for a federal USDA 9003 Biorefinery Assistance Program guaranteed loan.

In partnership with its key technology providers InEnTec and LanzaTech, Aemetis successfully optimized the integration of an advanced arc furnace and gas fermentation technologies to convert waste biomass into low carbon, renewable cellulosic ethanol and fish meal. The unit was built at the InEnTec Technology Center in Richland, Washington and demonstrated the fully integrated system, including biomass handling, gasification, gas clean up, waste treatment and distillation systems.

“The completion of the successful operation of the demonstration unit is the final technology step in securing a USDA loan guarantee for the $158 million cellulosic ethanol plant Aemetis is building in Riverbank, California,” said Eric McAfee, Chairman and CEO of Aemetis. “We believe that the integration of these technologies, and the high yields generated by the unit, demonstrate that Aemetis can successfully produce high value cellulosic ethanol from the 1.6 million tons of waste orchard wood and other renewable feedstocks in the Central Valley. With plans to expand the Riverbank plant and construct additional plants, Aemetis plans to be a leader in supplying California’s low carbon fuels mandates.”

With a 20-year feedstock supply agreement and a 55-year lease already signed, the 12 million gallon per year Riverbank plant is expected to begin operations in 2019.

For the demonstration unit, Aemetis used waste orchard wood and nut shells from almond and walnut trees as feedstock, gasified the biomass using a high temperature plasma gasification system to produce synthesis gas (“syngas”), cooled and cleaned the syngas, and supplied the syngas to a patented gas fermentation bioreactor to produce an ethanol broth. The broth was subsequently distilled to produce commercial grade ethanol.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India, the US and Europe. Aemetis operates a research and development laboratory, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the production or effectiveness of the demonstration facility, and the construction and operation of the cellulosic ethanol facility. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2016, and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
ksmith@pcgadvisory.com

Company Investor Relations/ Media Contact:

Todd Waltz
(408) 213-0940
investors@aemetis.com

$PVOTF Announces Acquisition of Thrudermic, LLC

Vancouver, British Columbia–(March 6, 2018) – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (“Pivot” or the “Company”) is pleased to announce the acquisition of Thrudermic, LLC (“TDL” or “Thrudermic”), a privately held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr. Borovsky, has been appointed Pivot’s Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director, Product Formulation.

The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products. On behalf of Pivot, Thrudermic recently filed three additional patent applications related to improved formulation and delivery for new routes of administration of cannabinoids and will increase the number of products in the Company’s pipeline.

“Thrudermic is very excited to become part of the Pivot organization. Our lipid-based nano-dispersion technology is well suited for the emerging cannabis industry. Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” states Dr. Borovsky.

Dr. Borovsky, formerly the director of research and development for Mead Corporation, received his Bachelor of Science degree in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry at Washington State University College of Pharmacy and was a Research Fellow in Synthetic Organic Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of Science, Israel.

Dr. Patrick Frankham, Pivot’s CEO, comments, “Thrudermic is Pivot’s fourth disruptive formulation and delivery platform for cannabinoids. We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to develop and commercialize therapeutic bio-cannabis products. They are highly experienced formulations experts with many years of pharmaceutical industry know-how. Pivot continues to position itself as a leader in the delivery of dosable bio-cannabis, something that consumers and regulatory agencies will demand as legalization occurs.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or Pivot Green Stream), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical); Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. PGS will seek to register these as Natural Health Products (NHP) for consumers. Products following the NHP pathway have shorter development cycles and can generate revenue faster than traditional pharmaceuticals. For more information please visit www.PivotPharma.com.

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PVOTF Closes C$5M Private Placement of Convertible Debentures

VANCOUVER, British Columbia, March 05, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB: PVOTF) (“Pivot” or the “Company”) is pleased to announce the closing of its previously announced private placement of convertible debentures for aggregate gross proceeds of C$5 million (the “Offering”). The Company intends to use the net proceeds of the Offering for the development of its pipeline of products, intellectual property acquisitions, and for working capital and general corporate purposes.

Pursuant to the Offering, the Company issued a total of C$5 million of 10% senior secured convertible debentures (the “Convertible Debentures”) which will mature 12 months following the date of their issuance and will be convertible at the option of the holder for a period of 12 months into common shares of the Company (“Common Shares”) at a conversion price of C$1.74 per Common Share (the “Conversion Price”), subject to adjustment of the Conversion Price in certain events.

Beginning on the date that is four months and one day following the issuance of the Convertible Debentures, the Company may force the conversion of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the Common Shares be greater than C$2.50 for any 20 consecutive trading days on the Canadian Stock Exchange, or such other exchange as the Common Shares are principally traded.

In connection with the Offering, Origin Merchant Securities Inc. received a finder’s fee of C$300,000, being 6% of the gross proceeds from the Offering and 172,413 non-transferable compensation warrants, being 6% of the gross proceeds from the Offering divided by the Conversion Price. Each compensation warrant entitles the holder to purchase one Common Share at the Conversion Price for a period of three years following the Closing of the Offering. All securities issued in connection with the Offering are subject to a four month hold period. For further details on the Offering, please refer to the Company’s news release dated February 27, 2018.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or its management, identify forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: info@pivotpharma.com

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX Announces New Company and Focused Financial Future

March 5, 2018

• CIIX announces spinoff of all hemp-related assets into a single private company
• CIIX shifts primary focus to core financial services, including cryptocurrency and blockchain technology

ChineseInvestors.com, Inc. (OTCQB: CIIX) has become the premier financial information website providing real-time market commentary, analysis and education-related services to Chinese-speaking investors. In 2018, the company is strategically focusing on building its core financial services business. CIIX has announced a spinoff of all hemp-related assets as the company explores new ways to expand.

CIIX announced plans to spin off all hemp-related assets into a single private company. CBD Biotechnology Co. Ltd., ChineseHempOil.com, Inc. and Hemp Logic Inc. will be combined into a single private company. Shareholders have the opportunity to take advantage of this dividend. CIIX CEO Warren Wang is encouraging holders of CIIX preferred stock to convert into common before May 31, 2018, the date of the spinoff.

The subsidiaries are well positioned to achieve significant growth. This spinoff is part of the groundwork to capitalize on the growing demand for CBD-based nutrition and health products in the U.S. and China. In January, these subsidiaries made a combined $100,000. The progress of the newly formed company will be overseen by CIIX, but the spinoff of CBD-focused assets will allow CIIX to focus on core financial services, including cryptocurrency and blockchain technology.

Since 1999, CIIX has been leading the way in providing financial information and education for Chinese-speaking investors. With the formation of the new company, CIIX plans to focus on its new cryptocurrency division and core financial education business, including ‘Bitcoin MultiMillionaire’, a daily newscast broadcast by CIIX as a free bitcoin education site in the Chinese language. The broadcast was launched in recognition of the growing interest in cryptocurrency among Chinese investors. CIIX provides reliable market information to help investors make informed decisions to meet their personal financial goals.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Marijuana Company of America Inc. (MCOA) Expands hempSMART™ Product Line with New Pet Products
• EVIO, Inc. (EVIO) Continues to Improve, Expanding EVIO Cannabis Testing Lab Services, Locations
• Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Opens the Door for Canadian Entrepreneurs with Dispensary Rollout Strategy

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$ETST Update on Human Trials of CBD-based Formula Targeting Opioid Crisis

NEW YORK, March 05, 2018 – via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of a recent Earth Science Tech, Inc. (OTC: ETST) press release titled “Earth Science Tech, Inc. Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic.”

To hear the Earth Science Tech, Inc. AudioPressRelease (APR) version, visit: http://nnw.fm/uR4QO

To read the original press release, visit: http://nnw.fm/YU5hv

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) is another NetworkNewsWire (NNW) Solution that can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$ZSAN Issuance of New U.S. Patent Covering M207 in Migraine

Patent extends proprietary position of M207 to 2037

FREMONT, Calif., March 02, 2018  — Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that the previously announced Notice of Allowance of our patent application titled “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines” has resulted in the issuance of a U.S. patent 9,918,932.  The inventors were Dr. Mahmoud Ameri, Dr. Don Kellerman, Dr. Yi Ao, and Dr. Peter Dadonna, all of whom are current or former employees of Zosano.  In February 2017, Zosano reported positive pivotal data from our Zotrip Phase 2/3 trial, in which subjects treated with the 3.8mg dose of M207 achieved statistical significance on the co-primary endpoints. The newly issued patent contains claims generated from formulation, preclinical and clinical studies, and highlights the unique aspects of the Zosano technologies and their applicability for treatment of migraine.

“We are pleased to have this important expansion of our patent estate for M207,” said John Walker, Chairman and Chief Executive Officer of Zosano. “This issuance supports our intellectual property strategy for our ADAM technology, and specifically M207.  We intend to pursue similar patent coverage for future products that Zosano develops internally, and in future partnerships.”

Zosano’s patent estate additionally includes other granted U.S. and foreign patents and pending patent applications covering our ADAM technology, including our microneedle technology, drug formulations, methods of use and applicators.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano’s proprietary Adhesive Dermally-Applied Microarray, or ADAM technology.  Zosano’s ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan.  Our ADAM technology delivers drug by penetrating the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin.  In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology.  The Company recently announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine.  Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” “unaudited,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K.. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200

$VSQTF Demonstrates Success in Recent Months – NetworkNewsBreaks

February 27, 2018

• Stock price increased by more than $3.00 in a two-month period
• Various acquisitions and partnerships in 2018
• Focused on incubating the new century’s technology giants

From numerous recent acquisitions to a stock price that has climbed dramatically in the past year, it’s an exciting time for blockchain-focused venture builder Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

Engaged in funding and empowering entrepreneurs to implement cutting-edge blockchain solutions, Victory Square is in the business of incubating a new generation of technology titans. The company’s diversified portfolio includes investment interests in the gaming, health care, artificial intelligence and virtual reality sectors, as well as others, and Victory Square’s portfolio companies are effectively disrupting a wide range of sectors across the global economy.

So far in 2018, Victory Square has announced various important acquisitions, including a 100 percent acquisition of established mobile games studio V2 Games Inc. (http://nnw.fm/39sNF), a 31.35 percent acquisition of emerging payment processing company PayVida Solutions Inc. (http://nnw.fm/IE4lM), and a 23.1 percent acquisition of emerging blockchain-focused fintech company Cassia Research Inc. (http://nnw.fm/1t9LV). The company has further forged various exciting strategic partnerships this year.

Victory Square’s stock has enjoyed an impressive boost in a short amount of time, climbing from $0.298 in October 2017 to an impressive $3.32 by December 2017. As of February 27, the company’s price has remained well above $2.00 per share.

Victory Square operates on the idea that impactful companies are built upon experimentation of bold ideas, and entrepreneurs working with the company have invaluable access to Victory Square’s education programs, global mentor network, distribution partners, creative workspaces, operational support and other resources to help them scale on an international level.

The company’s impressive brag sheet includes assisting more than 1,000 entrepreneurs and more than 500 startups to date, helping these entities collectively raise over $100 million and create more than 1,000 jobs.

Victory Square recognizes blockchain as the new major technology and the next key platform for innovation, with the ability to revolutionize the interconnections and operations of business and social structures. Leveraging its extensive expertise and standout prowess in building companies, Victory Square is hard at work identifying, incubating, advising and investing in the industry’s very best blockchain entrepreneurs.

For more information, visit the company’s website at www.VictorySquare.com

More from NetworkNewsWire

• EVIO, Inc. (EVIO) Continues to Improve, Expanding EVIO Cannabis Testing Lab Services, Locations
• Reign Sapphire Corp. (RGNP) Offering Custom-Made Jewelry that’s Memorable and Conflict-Free
• Imaging3, Inc. (IGNG) Breakthrough 3D Imaging Technology Offers Enhanced Portability, Safety

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX Featured on MoneyTV with Donald Baillargeon, 3/2

LOS ANGELES, CA / March 2, 2018 / CBD oil, the blockchain, water cleanup, solar and roofing, cannabis business, Chinese investors, who want the POTUS job; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week’s program include:

Chineseinvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang spoke of the company’s history and the recent focus on CBD oil products and cryptocurrency investor education.

Singlepoint, Inc. (OTCQB: SING) CEO Greg Lambrecht announced they have acquired a $1 million stake in cannabis cultivation land in California.

Solar Integrated Roofing Corporation (OTC PINK: SIRC) President David Savarese discussed deals with Angie’s List and Home Advisor.

Premier Biomedical, Inc. (OTC PINK: BIEI) CEO William Hartman discussed several aspects of the company’s business model.

OriginClear, Inc. (OTCQB: OCLN) CEO Riggs Eckelberry announced a water cleanup contract in Spain.

The Advocacy Network Founder Karl Schilling discussed the elements of achieving financial independence.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.

MoneyTV Executive Producer and Anchor Donald Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the television program Crowdfund Television, http://www.crowdfundtelevision.com.

MoneyTV with Donald Baillargeon television program, Copyright MMXVIII, all rights reserved. MoneyTV does not provide an analysis of companies’ financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4-month corporate profile with multiple appearances for a cash fee of $11,995.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producer, publisher or parent company of MoneyTV.

Contact:

Donald Baillargeon
info@moneytv.net
949 388 5267

$EAST Redneck Riviera Whiskey’s John Rich Throws a Party with Top Accounts in South Dakota

DEADWOOD, S.D. & PORTLAND, Ore.

Eastside Distilling, Inc. (NASDAQ: EAST), makers of award-winning craft spirits, and partner John Rich hosted a launch party to celebrate Redneck Riviera Whiskey (“RRW”) being available in South Dakota. Republic National Distributing Company (“RNDC”) has recently commenced distribution of Redneck Riviera Whiskey in South Dakota. Redneck Riviera Whiskey is a collaboration of Eastside Distilling and John Rich, the multi-platinum country-music artist and one-half of the award-winning duo Big & Rich. Please visit www.redneckriviera.com for more information on the brand. Download high-resolution images from the event here.

The SRO crowd dominated by various key liquor industry executives, media representatives and others took in a John Rich exclusive and intimate performance on Friday, February 23, 2018 at the Deadwood Mountain Grand Event Stage at the Deadwood Mountain Grand Resort in Deadwood, South Dakota.

“As I have previously stated, I share a great kinship with the history and the people of South Dakota,” commented John Rich. “My musical partner, Big Kenny Alphin and I have been inspired as songwriters by the history of the state, as well as by men like Vietnam veteran Niles Harris who inspired one of our songs and our commitment to Folds of Honor to help pay for college tuition for kids who have had a parent killed in combat. I can’t think of a better place and venue than Deadwood, South Dakota to celebrate with friends the rollout of our great American blend in this beautiful and historic state.”

Redneck Riviera Whiskey is currently now available or will be available very shortly in Texas, Louisiana, Alabama, Georgia, Mississippi, Florida, North Carolina, North and South Dakota, Oregon, Tennessee, Oklahoma and Nebraska. The list of states where Redneck Riviera Whiskey is distributed will grow as the product rollout continues.

About Redneck Riviera

Redneck Riviera is a privately held lifestyle brand that celebrates America’s hard-working men and women. Built for people who live to turn up the music and have fun with friends and family, Redneck Riviera is America’s ‘Work Hard, Play Hard’ brand that offers something for everyone who likes to rock the red, white and blue all year long. Launched in 2014, the brand brings these values to life through footwear, apparel, hospitality, food, spirits and licensed products in a variety of categories. Redneck Riviera has expanded its reach with the opening of honky-tonk bar Redneck Riviera Las Vegas and a Nashville location opening in 2018. More information can be found here.

About Eastside Distilling

Eastside Distilling, Inc. (NASDAQ: EAST) has been producing high-quality, award-winning craft spirits in Portland, Oregon since 2008. The company is distinguished by its highly decorated product lineup that includes Burnside Bourbon, West End American Whiskey, Goose Hollow Reserve, Below Deck Rums, Portland Potato Vodka, Hue-Hue Coffee Rum and a distinctive line of fruit infused spirits. Eastside Distilling is majority owner of Big Bottom Distilling (makers of The Ninety One Gin, Navy Strength Gin and Delta Rye whiskey) and the Redneck Riviera Whiskey Co. All Eastside, Big Bottom and Redneck Riviera spirits are crafted from natural ingredients for quality and taste. Eastside’s MotherLode Bottling subsidiary is one of the Northwest’s leading independent spirit bottlers and ready-to-drink canners. For more information visit: www.eastsidedistilling.com or follow the company on Twitter and Facebook.

Important Cautions Regarding Forward-Looking Statements

Certain matters discussed in this press release may be forward-looking statements. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company’s products in the market; the Company’s success in obtaining new customers; the Company’s success in product development; the Company’s ability to execute its business model and strategic plans; the Company’s success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the financial statements and related information contained in the Company’s Annual Report on Form 10-K and interim Quarterly Reports on Form 10-Q. Examples of forward-looking statements in this release may include statements related to our strategic focus, product verticals, anticipated revenue, and profitability. The Company assumes no obligation to update the cautionary information in this release.

Media Contact:
Wortman Works Media & Marketing
Jules Wortman, 615-260-9985
jwortman@wortmanworks.com
or
Company Contact:
Eastside Distilling
Steve Shum, CFO
971-888-4264
inquiries@eastsidedistilling.com
or
Investors:
Lytham Partners, LLC
Robert Blum, Joe Diaz or Joe Dorame
602-889-9700
east@lythampartners.com

$MNGA European Commission Awards European Joint Venture a $7.2 Million Grant

European Government Funding Expected to Expand Scope of German-Based Biofuels Pilot Program in 2018

$TENX Announces New Scientific Publication of Preclinical Data

MORRISVILLE, N.C.

Tenax Therapeutics, Inc. (Nasdaq: TENX) today announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation. The study was titled “Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure” and found that chronic administration of levosimendan improved right heart function. Dr. Hansen and colleagues assessed the effects of levosimendan in an experimental model of right heart failure. The authors conclude the study results support the “potential therapeutic value of chronic levosimendan in treatment RV failure.”

This is the second study published in recent months by Dr. Hansen and colleagues who have investigated the potential benefits of levosimendan treatment for right heart failure secondary to pulmonary hypertension. This group published similar findings in October 2017 in Journal of Cardiovascular Pharmacology in a study titled, “Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension.” The results from this preclinical study resulted in the authors concluding that “Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.”

Observations from these preclinical studies are in keeping with previous clinical trials of levosimendan in pulmonary hypertension patients conducted by Kleber et al in 2009 and Jiang et al in 2017. Each provided evidence that levosimendan may provide benefits to patients with pulmonary hypertension, including those with coexisting right heart failure.

Michael Jebsen, Interim CEO of Tenax Therapeutics stated, “The promising findings reported in the scientific literature provide additional support to our hypothesis that levosimendan has the potential to offer significant benefits in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) patients through improvements in right heart function. We believe that levosimendan’s unique mechanisms of action will provide an alternative therapy for PH-HFpEF patients who currently have no effective or approved therapies to help manage their disease. Our Phase 2 study for this indication is anticipated to begin in the later part of next quarter.”

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on licensing, development, and commercialization of drugs that address conditions with high unmet medical need. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan. For more information, visit www.tenaxthera.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the company’s control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in the company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 16, 2017, its quarterly report on Form 10-Q filed on November 9, 2017 as well as its other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

IRTH Communications
Robert Haag, 800-439-1433
TENX@irthcommunications.com

$ETST Scientifically Advancing CBD

March 1, 2018

• Company committed to scientific validation of CBD efficacy
• Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
• With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://cnw.fm/ak2Pv), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• Global Payout, Inc. (GOHE) Leading the Way in Fintech Solutions
• Skinvisible, Inc.’s (SKVI) Potential Merger Set to Deliver an Alternative as Opioid Crisis Deepens
• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Seven-Year Licensing Agreement with Cannfections Group, Inc.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net